Our Pipeline

Our rapidly advancing clinical programs in Duchenne muscular dystrophy, Marburg and influenza represent the foundation for a growing and diverse pipeline in rare and infectious diseases.

 
 
 
 

Our therapeutic development programs include lead clinical candidates for Duchenne muscular dystrophy and infections of public health significance, including influenza and multi-drug resistant bacterial infections.

  • PROGRAM
  • DISCOVERY
  • preclinical
  • PHASE 1
  • PHASE 2
  • PHASE 3
 

RARE DISEASES

  • DMD EXON 51 (ETEPLIRSEN / AVI-4658)
  • DMD EXON 53 (SRP-4053)
  • DMD EXON 45 (SRP-4045)
  • DMD EXON 44
  • DMD EXON 52 (SRP-4052)
  • DMD EXON 50
  • DMD EXON 43
  • DMD EXON 55
  • DMD EXON 8
  • DMD EXON 35
  • NON-DMD TARGETS
 

INFECTIOUS DISEASES

  • AVI-7288
    MARBURG VIRUS
  • AVI-7537
    EBOLA VIRUS
  • AVI-7100
    INFLUENZA
  • VIRAL PMO-X
    DENGUE
  • BACTERIAL PPMO
    TB
  • UNDISCLOSED TARGETS